Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Iterum Therapeutics Plc (ITRM)

Iterum Therapeutics Plc (ITRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,946
  • Shares Outstanding, K 13,959
  • Annual Sales, $ 40 K
  • Annual Income, $ -103,130 K
  • 60-Month Beta 1.76
  • Price/Sales 1,051.15
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.35
  • Number of Estimates 2
  • High Estimate -1.23
  • Low Estimate -1.47
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.40 +99.14%
on 03/18/20
2.95 -5.42%
on 03/25/20
-0.08 (-2.79%)
since 02/27/20
3-Month
1.40 +99.14%
on 03/18/20
5.30 -47.36%
on 12/30/19
-1.96 (-41.26%)
since 12/27/19
52-Week
1.40 +99.14%
on 03/18/20
9.30 -70.00%
on 04/12/19
-5.21 (-65.13%)
since 03/27/19

Most Recent Stories

More News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1--

ITRM : 2.79 (unch)
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens...

ITRM : 2.79 (unch)
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors

Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant...

ITRM : 2.79 (unch)
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens...

ITRM : 2.79 (unch)
Iterum Down as Sulopenem Antibiotic Fails in Phase III Study

Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.

GSK : 36.44 (-2.17%)
PFE : 30.90 (-2.68%)
SPRO : 7.76 (-3.96%)
ITRM : 2.79 (unch)
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to treat infections caused by multi-drug resistant pathogens in both...

ITRM : 2.79 (unch)
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens...

ITRM : 2.79 (unch)
Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates

Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

ITRM : 2.79 (unch)
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights

--Phase 3 topline data from the cIAI trial expected shortly--

ITRM : 2.79 (unch)
Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to Decline

Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ITRM : 2.79 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ITRM with:

Business Summary

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated...

See More

Key Turning Points

2nd Resistance Point 3.19
1st Resistance Point 2.99
Last Price 2.79
1st Support Level 2.50
2nd Support Level 2.22

See More

52-Week High 9.30
Fibonacci 61.8% 6.28
Fibonacci 50% 5.35
Fibonacci 38.2% 4.42
Last Price 2.79
52-Week Low 1.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar